Abstract:BackgroundChemotherapy induced nausea and vomitting (CINV) is associated with significant deterioration in quality of life. The standard antiemetic therapy for highly emetogenic chemotherapy are combination therapies, and dexamethasone is a necessary component. However, dexamethasone has diverse side effects and it may not be an appropriate antiemetic for use in immunotherapy. Guidelines recommend using olanzapine (10mg) in preventing CINV, but excessive sedation was reported. A trail reported that lower dose olanzapine (5mg) was effective in control of CINV and had less serious sedation events. We initiated this trial to validate whether olanzapine (5mg) could be a non-inferiority alternative of dexamethasone in the triplet antiemetic combination therapy.MethodsThe predicted sample size in this trial (NCT04437017) is 548 (power=80%, α=0.05, non-inferiority margin=10%). Eligible patients are randomized in a 1: 1 ratio into two groups to receive olanzapine or dexamethasone plus a 5-HT3 receptor antagonist (5-HT3 RA) and a NK-1 receptor antagonist (NK-1 RA). The primary endpoint is 0–120 h complete response (CR) rate, and the secondary endpoints are 25–120 h CR rate and 0–120 h no nausea rate. The endpoints and side effects will be recorded after the initiation of chemotherapy for 5 days.ResultsPatients in the olanzapine group achieved a 0–120 h CR rate (83.6% v.s. 84.9%, difference [one-sided 95% CI]: 1.2% [-∞, 6.4%], Pnoninferiority = 0.003), 25–120 h CR rate (85.5% v.s. 85.6%, difference [one-sided 95% CI]: 0.1% [-∞, 5.1%], Pnoninferiority = 0.024) and 0–120 h no nausea rate (38.7% v.s. 39.9%, difference [one-sided 95% CI]: 1.2% [-∞, 8.1%], Pnoninferiority = 0.001) non-inferior to that in patients in the olanzapine group. Moreover, side effects such as constipation (P = 0.045), hiccups (P < 0.001) as well as insomnia (P < 0.001) were more frequent in patients receiving dexamethasone than in those receiving olanzapine.ConclusionsOlanzapine (5mg) could be a non-inferiority alternative of dexamethasone in the triplet combination anti-emetic therapy and has less side effects than dexamethasone.Legal entity responsible for the studyThe Fifth Affiliated Hospital of Sun Yat-sen University.FundingBeijing Xisike Clinical Oncology Research Foundation and the Investigator-Initiated Clinical Trial foundation of the Fifth Affiliated hospital of Sun Yat-sen University.DisclosureAll authors have declared no conflicts of interest. BackgroundChemotherapy induced nausea and vomitting (CINV) is associated with significant deterioration in quality of life. The standard antiemetic therapy for highly emetogenic chemotherapy are combination therapies, and dexamethasone is a necessary component. However, dexamethasone has diverse side effects and it may not be an appropriate antiemetic for use in immunotherapy. Guidelines recommend using olanzapine (10mg) in preventing CINV, but excessive sedation was reported. A trail reported that lower dose olanzapine (5mg) was effective in control of CINV and had less serious sedation events. We initiated this trial to validate whether olanzapine (5mg) could be a non-inferiority alternative of dexamethasone in the triplet antiemetic combination therapy. Chemotherapy induced nausea and vomitting (CINV) is associated with significant deterioration in quality of life. The standard antiemetic therapy for highly emetogenic chemotherapy are combination therapies, and dexamethasone is a necessary component. However, dexamethasone has diverse side effects and it may not be an appropriate antiemetic for use in immunotherapy. Guidelines recommend using olanzapine (10mg) in preventing CINV, but excessive sedation was reported. A trail reported that lower dose olanzapine (5mg) was effective in control of CINV and had less serious sedation events. We initiated this trial to validate whether olanzapine (5mg) could be a non-inferiority alternative of dexamethasone in the triplet antiemetic combination therapy. MethodsThe predicted sample size in this trial (NCT04437017) is 548 (power=80%, α=0.05, non-inferiority margin=10%). Eligible patients are randomized in a 1: 1 ratio into two groups to receive olanzapine or dexamethasone plus a 5-HT3 receptor antagonist (5-HT3 RA) and a NK-1 receptor antagonist (NK-1 RA). The primary endpoint is 0–120 h complete response (CR) rate, and the secondary endpoints are 25–120 h CR rate and 0–120 h no nausea rate. The endpoints and side effects will be recorded after the initiation of chemotherapy for 5 days. The predicted sample size in this trial (NCT04437017) is 548 (power=80%, α=0.05, non-inferiority margin=10%). Eligible patients are randomized in a 1: 1 ratio into two groups to receive olanzapine or dexamethasone plus a 5-HT3 receptor antagonist (5-HT3 RA) and a NK-1 receptor antagonist (NK-1 RA). The primary endpoint is 0–120 h complete response (CR) rate, and the secondary endpoints are 25–120 h CR rate and 0–120 h no nausea rate. The endpoints and side effects will be recorded after the initiation of chemotherapy for 5 days. ResultsPatients in the olanzapine group achieved a 0–120 h CR rate (83.6% v.s. 84.9%, difference [one-sided 95% CI]: 1.2% [-∞, 6.4%], Pnoninferiority = 0.003), 25–120 h CR rate (85.5% v.s. 85.6%, difference [one-sided 95% CI]: 0.1% [-∞, 5.1%], Pnoninferiority = 0.024) and 0–120 h no nausea rate (38.7% v.s. 39.9%, difference [one-sided 95% CI]: 1.2% [-∞, 8.1%], Pnoninferiority = 0.001) non-inferior to that in patients in the olanzapine group. Moreover, side effects such as constipation (P = 0.045), hiccups (P < 0.001) as well as insomnia (P < 0.001) were more frequent in patients receiving dexamethasone than in those receiving olanzapine. Patients in the olanzapine group achieved a 0–120 h CR rate (83.6% v.s. 84.9%, difference [one-sided 95% CI]: 1.2% [-∞, 6.4%], Pnoninferiority = 0.003), 25–120 h CR rate (85.5% v.s. 85.6%, difference [one-sided 95% CI]: 0.1% [-∞, 5.1%], Pnoninferiority = 0.024) and 0–120 h no nausea rate (38.7% v.s. 39.9%, difference [one-sided 95% CI]: 1.2% [-∞, 8.1%], Pnoninferiority = 0.001) non-inferior to that in patients in the olanzapine group. Moreover, side effects such as constipation (P = 0.045), hiccups (P < 0.001) as well as insomnia (P < 0.001) were more frequent in patients receiving dexamethasone than in those receiving olanzapine. ConclusionsOlanzapine (5mg) could be a non-inferiority alternative of dexamethasone in the triplet combination anti-emetic therapy and has less side effects than dexamethasone. Olanzapine (5mg) could be a non-inferiority alternative of dexamethasone in the triplet combination anti-emetic therapy and has less side effects than dexamethasone.

Efficacy of Olanzapine Combined with the Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Sub-Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial (J-FORCE).

Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Evaluating Olanzapine 5 Mg Combined with Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin-Based Chemotherapy: J-FORCE Study.

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Olanzapine 5mg in Combination with Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin-Based Chemotherapy (J-FORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study

Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

Abstract RF01-08: A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE)

Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial.

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)

A New Standard Prophylaxis for Emesis Caused by Cisplatin? – Authors' Reply

Comment on "Dexamethasone-sparing on days 2–4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)"

Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy

Olanzapine Combined with 5-Hydroxytryptamine Type 3 Receptor Antagonist (5-HT3 RA) Plus Dexamethasone for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in High and Moderate Emetogenic Chemotherapy: a Systematic Review and Meta-Analysis of Randomised Controlled Trials

Efficacy Of Olanzapine For The Prophylaxis Of Chemotherapy-Induced Nausea And Vomiting: A Meta-Analysis

LBA64 Olanzapine, an Alternative to Dexamethasone for Preventing Nausea and Vomiting Induced by Cisplatin-Based Doublet Highly Emetogenic Chemotherapy: A Non-Inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase III Clinical Trial

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)

Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I